false 0001496671 0001496671 2022-05-10 2022-05-10





Washington, D.C. 20549







Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 10, 2022



Calithera Biosciences, Inc.

(Exact name of registrant as specified in its charter)




Delaware   001-36644   27-2366329
(State or other jurisdiction
of incorporation)
File Number)
  (IRS Employer
Identification No.)

343 Oyster Point Blvd. Suite 200

South San Francisco, California

(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (650) 870-1000



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class





Name of each exchange
on which registered

Common Stock, 0.0001 par value   CALA   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




Item 2.02. Results of Operations and Financial Condition.

On May 10, 2022, Calithera Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2022. A copy of this press release is attached hereto as Exhibit 99.1.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.






Press Release, dated May 10, 2022

104    Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)


Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


    Calithera Biosciences, Inc.
Dated: May 10, 2022    

/s/ Susan M. Molineaux

      Susan M. Molineaux  
      President and Chief Executive Officer  
EX-99.1 2 d338475dex991.htm EX-99.1 EX-99.1

Exhibit 99.1



Calithera Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights

— Conference Call and Webcast Scheduled for 2:00 p.m. PT / 5:00 p.m. ET on Tuesday, May 10, 2022 —

SOUTH SAN FRANCISCO, Calif., May 10, 2022 (GLOBE NEWSWIRE) – Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the first quarter ended March 31, 2022.

“We made significant headway in the transfer of mivavotinib and sapanisertib materials to Calithera during the first quarter and are well into site start-up activities. We are on track to begin enrolling patients in both mivavotinib and sapanisertib trials in the second quarter of 2022 and expect to share data from these studies by the first quarter of 2023,” said Susan Molineaux, PhD, president and chief executive officer of Calithera. “We are also excited about our preclinical synthetic lethality program, having presented the first data from our internally-discovered, first-of-their-kind VPS4A inhibitors at the AACR Annual Meeting. This year has shaped up to be an exciting one for Calithera, given the potential we see in both our clinical and preclinical programs.”

First Quarter 2022 and Recent Highlights



Mivavotinib (SYK inhibitor): Based on clinical data showing enhanced activity of mivavotinib in activated B-cell-like (ABC) diffuse large B-cell lymphoma (DLBCL) and preclinical data demonstrating enhanced SYK activity and inhibition in DLBCL with MyD88/CD79 mutations, Calithera designed a phase 2 trial of mivavotinib in relapsed or refractory non-GCB (ABC) DLBCL with enrichment of MYD88/CD79b-mutated tumors using liquid next-generation sequencing (NGS) testing. The phase 2a portion of the study will confirm activity in the biomarker-defined subsets and further refine dose and schedule. The trial will enroll non-GCB (ABC) DLBCL patients based on Hans algorithm, and researchers will collect MyD88 and CD79 mutation status using ctDNA-based liquid NGS to accrue a pre-specified number of patients harboring MyD88 or CD79b mutations. Approximately 50% of all ABC DLBCL tumors have one or both of these mutations. Calithera anticipates the first patient enrolled in the second quarter of 2022. Data generated from this study could position the company to initiate a study with registrational intent in biomarker-specific populations in DLBCL.



Sapanisertib (Dual mTORC 1/2 inhibitor): In a recent investigator-led study, sapanisertib demonstrated durable single-agent activity in patients with heavily pretreated NRF2 (NFE2L2)-mutated squamous non-small cell lung cancer (NSCLC). These mutations occur in approximately 15% of patients with squamous NSCLC. Calithera is initiating a phase 2 study intended to strengthen the existing data in patients with NRF2-mutated squamous NSCLC and evaluate its activity in NRF2 wildtype (WT) squamous NSCLC. Sapanisertib has the potential to be a first-in-class treatment for individuals with NRF2-mutated squamous NSCLC, a patient population with poorer prognosis, unmet clinical need, and no targeted therapies. Sapanisertib could also be a possible treatment for other NRF2-mutated cancers beyond NSCLC. Calithera anticipates the first patient enrolled in this study in the second quarter of 2022.



Presented data on its novel series of VPS4A inhibitors. Calithera presented the first data from its preclinical synthetic lethality pipeline at the American Association for Cancer Research (AACR) 2022 Annual Meeting. The presented poster detailed Calithera’s discovery of a novel series of VPS4A (vacuolar protein sorting-associated protein 4A) inhibitors that are currently advancing through lead optimization. These data validate the synthetic lethal interaction between the gene paralogs VPS4A and VPS4B, and we believe, provide the first preclinical evidence supporting a newly discovered series of compounds designed to target these proteins for cancer treatment. To our knowledge, these are the first active, on-target VPS4 inhibitors described to date.



Closed a $10.0 Million Underwritten Public Offering of Common Stock and Warrants to Purchase Common Stock. On April 1, 2022, Calithera closed an underwritten public offering of 18,518,519 shares of


its common stock at a combined price to the public of $0.54 per share and accompanying warrants. Each share of common stock is accompanied by a warrant to purchase one share of common stock at an exercise price of $0.54 per share, which is immediately exercisable and will expire 18 months from the date of issuance, or a short-term warrant, and a warrant to purchase one share of common stock at an exercise price of $0.54 per share, which is immediately exercisable and will expire 5 years from the date of issuance, or a long-term warrant. Calithera received gross proceeds of $10.0 million, resulting in $8.5 million of net proceeds after deducting underwriting discounts and commissions and offering expenses.

Selected First Quarter 2022 Financial Results

Cash and cash equivalents totaled $44.7 million at March 31, 2022, which Calithera expects, together with proceeds from its public offering, will be sufficient to meet its operating plan through the second quarter of 2023.

Research and development expenses for the first quarter 2022 were $9.6 million, compared to $15.3 million in the same period prior year. The decrease of $5.8 million was primarily due to a decrease in the telaglenastat program, partially offset by increases in the sapanisertib and mivavotinib programs.

General and administrative expenses for the first quarter 2022 were $4.3 million, compared to $5.4 million in the same period prior year. The decrease of $1.2 million was primarily due to decreases in personnel-related costs.

Net loss for the three months ended March 31, 2022 was $13.8 million.

Conference Call Information

Calithera will host an update conference call today, Tuesday, May 10, at 2:00 p.m. Pacific Time/5:00 p.m. Eastern Time. The call may be accessed by dialing (855) 783-2599 (domestic) or (631) 485-4877 (international) and referring to conference ID 4979639. To access the live audio webcast or the subsequent archived recording, visit the Investors section of the Calithera website at www.calithera.com. The webcast will be recorded and available for replay on Calithera’s website for 30 days.

About Calithera

Calithera Biosciences is a clinical-stage, precision oncology biopharmaceutical company developing targeted therapies to redefine treatment for biomarker-specific patient populations. Driven by a commitment to rigorous science and a passion for improving the lives of people impacted by cancer and other life-threatening diseases, Calithera is advancing a robust pipeline of investigational, small-molecule oncology compounds with a biomarker-driven approach that targets genetic vulnerabilities in cancer cells to deliver new therapies for patients suffering from aggressive hematologic and solid tumor cancers for which there are currently limited treatment options.

Calithera is headquartered in South San Francisco, California. For more information about Calithera, please visit www.calithera.com.

Forward Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “anticipate,” “estimate,” “intend,” “poised” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those related to the safety, tolerability and efficacy of Calithera’s product candidates, the overall advancement of Calithera’s product candidates in preclinical development and clinical trials, including Calithera’s plan to initiate two phase 2 clinical trials for mivavotinib and sapanisertib and plan to share data from these trials by the first quarter 2023, Calithera’s ability to potentially initiate registrational studies in biomarker-specific populations in DLBC and relapsed or refractory squamous NSCLC, the unmet need in the treatment of patients with advanced disease, and management’s expectation that Calithera’s cash and cash equivalents will be sufficient to meet its operating plan through the second quarter of 2023. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. The potential product candidates that Calithera develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all. In addition, clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release. Such product candidates may not be beneficial to patients or be successfully commercialized. The failure to meet expectations with respect to any of the foregoing matters may have a negative effect on Calithera’s stock price. Additional information concerning these and other risk factors affecting Calithera’s business can be found in Calithera’s periodic filings with the Securities and

Exchange Commission at www.sec.gov. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Calithera disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.

Calithera Biosciences, Inc.

Selected Consolidated Statements of Operations Financial Data

(in thousands, except per share amounts)



     Three Months Ended
March 31,
     2022     2021  

Operating expenses:


Research and development

     9,566       15,339  

General and administrative

     4,260       5,428  







Total operating expenses

     13,826       20,767  







Loss from operations

     (13,826     (20,767

Interest and other income (expense), net

     (9     372  







Net loss

   $ (13,835   $ (20,395







Net loss per share, basic and diluted

   $ (0.18   $ (0.28







Weighted average common shares used to compute net loss per share, basic and diluted

     78,468       72,247  







Calithera Biosciences, Inc.

Selected Consolidated Balance Sheet Financial Data

(in thousands)



     March 31,
    December 31,

Balance Sheet Data:


Cash and cash equivalents

   $ 44,664     $ 59,537  

Working capital

     35,894       47,446  

Total assets

     50,236       64,756  

Total liabilities

     12,670       15,672  

Convertible preferred stock

     40,702       40,702  

Accumulated deficit

     (505,161     (491,326

Total stockholders’ (deficit) equity

     (3,136     8,382  


Stephanie Wong




Burns McClellan

Lee Roth




Sam Brown, Inc.

Hannah Hurdle



EX-101.SCH 3 cala-20220510.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 cala-20220510_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 cala-20220510_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g338475g0510130512255.jpg GRAPHIC begin 644 g338475g0510130512255.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information
May 10, 2022
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001496671
Document Type 8-K
Document Period End Date May 10, 2022
Entity Registrant Name Calithera Biosciences, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-36644
Entity Tax Identification Number 27-2366329
Entity Address, Address Line One 343 Oyster Point Blvd.
Entity Address, Address Line Two Suite 200
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code (650)
Local Phone Number 870-1000
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, 0.0001 par value
Trading Symbol CALA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 d338475d8k_htm.xml IDEA: XBRL DOCUMENT 0001496671 2022-05-10 2022-05-10 false 0001496671 8-K 2022-05-10 Calithera Biosciences, Inc. DE 001-36644 27-2366329 343 Oyster Point Blvd. Suite 200 South San Francisco CA 94080 (650) 870-1000 false false false false Common Stock, 0.0001 par value CALA NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.calithera.com//20220510/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d338475d8k.htm cala-20220510.xsd cala-20220510_lab.xml cala-20220510_pre.xml d338475dex991.htm http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d338475d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d338475d8k.htm" ] }, "labelLink": { "local": [ "cala-20220510_lab.xml" ] }, "presentationLink": { "local": [ "cala-20220510_pre.xml" ] }, "schema": { "local": [ "cala-20220510.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "cala", "nsuri": "http://www.calithera.com/20220510", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d338475d8k.htm", "contextRef": "duration_2022-05-10_to_2022-05-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.calithera.com//20220510/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d338475d8k.htm", "contextRef": "duration_2022-05-10_to_2022-05-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.calithera.com//20220510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.calithera.com//20220510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.calithera.com//20220510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.calithera.com//20220510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.calithera.com//20220510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.calithera.com//20220510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.calithera.com//20220510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.calithera.com//20220510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.calithera.com//20220510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.calithera.com//20220510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.calithera.com//20220510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.calithera.com//20220510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.calithera.com//20220510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.calithera.com//20220510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.calithera.com//20220510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.calithera.com//20220510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.calithera.com//20220510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.calithera.com//20220510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.calithera.com//20220510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.calithera.com//20220510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.calithera.com//20220510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.calithera.com//20220510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.calithera.com//20220510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001193125-22-146268-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-146268-xbrl.zip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�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